- Home
- HOLX
HOLX
Hologic Inc.
as 07-26-2024 4:00pm EST
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Upcoming Earnings Alert:
Get ready for potential market movements as Hologic Inc. HOLX prepares to release earnings report on 29 Jul 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 17.9B | IPO Year: | 1990 |
| Target Price: | $85.55 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.95 | EPS Growth: | -35.00 |
| 52 Week Low/High: | $64.02 - $81.09 | Next Earning Date: | 07-29-2024 |
| Revenue: | $3,960,600,000 | Revenue Growth: | -2.37% |
| Revenue Growth (this year): | 2.05% | Revenue Growth (next year): | 5.47% |
Stock Insider Trading Activity of Hologic Inc. (HOLX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MACMILLAN STEPHEN P | HOLX | Chairman, President and CEO | Jul 17 '24 | Sell | $80.13 | 3,672 | $294,222.67 | 1,157,562 | SEC Form 4 |
| GARRETT SCOTT T | HOLX | Director | Mar 14 '24 | Sell | $75.50 | 16,441 | $1,241,295.50 | 48,611 | SEC Form 4 |
| CRAWFORD SALLY | HOLX | Director | Mar 7 '24 | Sell | $76.40 | 9,039 | $690,606.72 | 132,927 | SEC Form 4 |
| Dockendorff Charles J | HOLX | Director | Mar 7 '24 | Sell | $76.21 | 1,465 | $111,647.65 | 1,572 | SEC Form 4 |
| Oberton Karleen Marie | HOLX | Chief Financial Officer | Jan 29 '24 | Sell | $75.00 | 14,940 | $1,120,500.00 | 103,916 | SEC Form 4 |
| Dockendorff Charles J | HOLX | Director | Jan 2 '24 | Sell | $72.00 | 16,017 | $1,153,224.00 | 1,465 | SEC Form 4 |
| GARRETT SCOTT T | HOLX | Director | Dec 11 '23 | Sell | $68.71 | 10,000 | $687,116.00 | 47,039 | SEC Form 4 |
| MACMILLAN STEPHEN P | HOLX | Chairman, President and CEO | Nov 29 '23 | Sell | $70.41 | 47,711 | $3,359,188.38 | 1,239,088 | SEC Form 4 |
Latest Hologic Inc. News
HOLX Breaking Stock News: Dive into HOLX Ticker-Specific Updates for Smart Investing
Zacks
8 hours ago
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
Zacks
9 hours ago
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
Medical Device Network
15 hours ago
Hologic acquires UK’s Endomagnetics for $310m
MT Newswires
a day ago
Hologic Completes Endomagnetics Acquisition for $310 Million
Zacks
a day ago
Gear Up for Hologic (HOLX) Q3 Earnings: Wall Street Estimates for Key Metrics
Business Wire
2 days ago
Hologic Completes Acquisition of Endomagnetics Ltd
Zacks
2 days ago
PacBio's (PACB) Revio System to Boost Novogene's German Lab
Zacks
3 days ago
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
Compare HOLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOLX Hologic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.